Literature DB >> 26498939

Short- and long-term inhibition of cardiac inward-rectifier potassium channel current by an antiarrhythmic drug bepridil.

Fangfang Ma1,2, Hiroki Takanari1, Kimiko Masuda1, Masaki Morishima1, Katsushige Ono3.   

Abstract

Bepridil is an effective antiarrhythmic drug on supraventricular and ventricular arrhythmias, and inhibitor of calmodulin. Recent investigations have been elucidating that bepridil exerts antiarrhythmic effects through its acute and chronic application for patients. The aim of this study was to identify the efficacy and the potential mechanism of bepridil on the inward-rectifier potassium channel in neonatal rat cardiomyocytes in acute- and long-term conditions. Bepridil inhibited inward-rectifier potassium current (I K1) as a short-term effect with IC50 of 17 μM. Bepridil also reduced I K1 of neonatal cardiomyocytes when applied for 24 h in the culture medium with IC50 of 2.7 μM. Both a calmodulin inhibitor (W-7) and an inhibitor of calmodulin-kinase II (KN93) reduced I K1 when applied for 24 h as a long-term effect in the same fashion, suggesting that the long-term application of bepridil inhibits I K1 more potently than that of the short-term application through the inhibition of calmodulin kinase II pathway in cardiomyocytes.

Entities:  

Keywords:  Bepridil; Calmodulin; Inward-rectifier K+ channel; KN93; W-7

Mesh:

Substances:

Year:  2015        PMID: 26498939     DOI: 10.1007/s00380-015-0762-1

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  33 in total

1.  Bepridil inhibits sub-acute phase of atrial electrical remodeling in canine rapid atrial stimulation model.

Authors:  Daisuke Sato; Shinichi Niwano; Ryuta Imaki; Yoshihiko Masaki; Sae Sasaki; Masaru Yuge; Shoji Hirasawa; Takeshi Sasaki; Masahiko Moriguchi; Hiroe Niwano; Hirokuni Yoshimura; Tohru Izumi
Journal:  Circ J       Date:  2006-02       Impact factor: 2.993

2.  Characterization of cardiac oxidative stress levels in patients with atrial fibrillation.

Authors:  Ayako Okada; Yuichiro Kashima; Takeshi Tomita; Takahiro Takeuchi; Kazunori Aizawa; Masafumi Takahashi; Uichi Ikeda
Journal:  Heart Vessels       Date:  2014-09-27       Impact factor: 2.037

3.  Stabilization of Kv1.5 channel protein by bepridil through its action as a chemical chaperone.

Authors:  Sayuri Suzuki; Yasutaka Kurata; Peili Li; Tomomi Notsu; Akira Hasegawa; Nobuhito Ikeda; Masaru Kato; Junichiro Miake; Shinji Sakata; Goshi Shiota; Akio Yoshida; Haruaki Ninomiya; Katsumi Higaki; Kazuhiro Yamamoto; Yasuaki Shirayoshi; Ichiro Hisatome
Journal:  Eur J Pharmacol       Date:  2012-09-28       Impact factor: 4.432

4.  Voltage-dependent and frequency-independent inhibition of recombinant Cav3.2 T-type Ca2+ channel by bepridil.

Authors:  Tomoko Uchino; Tae-Seong Lee; Toshihiko Kaku; Noboru Yamashita; Takayuki Noguchi; Katsushige Ono
Journal:  Pharmacology       Date:  2005-04-25       Impact factor: 2.547

5.  Differences in atrial fibrillation properties under vagal nerve stimulation versus atrial tachycardia remodeling.

Authors:  Grigorios Katsouras; Masao Sakabe; Philippe Comtois; Ange Maguy; Brett Burstein; Peter G Guerra; Mario Talajic; Stanley Nattel
Journal:  Heart Rhythm       Date:  2009-07-21       Impact factor: 6.343

6.  Class I and IV antiarrhythmic drugs and cytosolic calcium regulate mRNA encoding the sodium channel alpha subunit in rat cardiac muscle.

Authors:  H J Duff; J Offord; J West; W A Catterall
Journal:  Mol Pharmacol       Date:  1992-10       Impact factor: 4.436

7.  Transcription factors Csx/Nkx2.5 and GATA4 distinctly regulate expression of Ca2+ channels in neonatal rat heart.

Authors:  Yan Wang; Masaki Morishima; Mingqi Zheng; Tomoko Uchino; Kazuaki Mannen; Akira Takahashi; Yutaka Nakaya; Issei Komuro; Katsushige Ono
Journal:  J Mol Cell Cardiol       Date:  2007-03-30       Impact factor: 5.000

8.  Interactions of calmodulin antagonists with calcium antagonists binding sites.

Authors:  P Schaeffer; C Lugnier; J C Stoclet
Journal:  Eur J Pharmacol       Date:  1991-04-25       Impact factor: 4.432

9.  SD-3212, a new class I and IV antiarrhythmic drug: a potent inhibitor of the muscarinic acetylcholine-receptor-operated potassium current in guinea-pig atrial cells.

Authors:  Y Hara; H Nakaya
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

10.  DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Authors:  David S Wishart; Craig Knox; An Chi Guo; Savita Shrivastava; Murtaza Hassanali; Paul Stothard; Zhan Chang; Jennifer Woolsey
Journal:  Nucleic Acids Res       Date:  2006-01-01       Impact factor: 16.971

View more
  3 in total

1.  Novel drug candidate for the treatment of several soft‑tissue sarcoma histologic subtypes: A computational method using survival‑associated gene signatures for drug repurposing.

Authors:  Xia Yang; Wen-Ting Huang; Hua-Yu Wu; Rong-Quan He; Jie Ma; An-Gui Liu; Gang Chen
Journal:  Oncol Rep       Date:  2019-02-26       Impact factor: 3.906

2.  Blockade of the forward Na+ /Ca2+ exchanger suppresses the growth of glioblastoma cells through Ca2+ -mediated cell death.

Authors:  Hui-Jie Hu; Shan-Shan Wang; Yan-Xia Wang; Yan Liu; Xue-Mei Feng; Ying Shen; Liang Zhu; Hong-Zhuan Chen; Mingke Song
Journal:  Br J Pharmacol       Date:  2019-06-17       Impact factor: 8.739

3.  Bepridil, a class IV antiarrhythmic agent, can block the TREK-1 potassium channel.

Authors:  Ying Wang; Zhijie Fu; Zhiyong Ma; Na Li; Hong Shang
Journal:  Ann Transl Med       Date:  2021-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.